Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Takeda pleased to receive positive NICE guidance for brentuximab vedotin (ADCETRIS®?) in relapsed / refractory (R/R) systemic anaplastic large cell lymphoma (sALCL) 1

Takeda
Posted on: 25 Aug 17

NICE decision ensures continuity of access for the majority of patients with R/R sALCL to a medicine that has transformed patient care for this rare cancer since its introduction in 2012.

 

Takeda is disappointed that NICE has included an access restriction based on ECOG performance status within the FAD without any discussion on the topic at either appraisal committee meeting. This restriction negatively impacts a very small group of patients who may now struggle to gain access to potentially their only viable treatment option.

 

Takeda UK Ltd, High Wycombe: Thursday 24th August 2017

  • Through hard work, flexibility and determination, Takeda, supported by the clinical and patient community, has successfully overturned previous negative draft guidance published on brentuximab vedotin in the treatment of R/R sALCL.  This ensures long-term access to this vital standard of care ggestreatment for adults with R/R sALCL in England, Wales and Northern Ireland1
  • NICE’s final appraisal document (FAD) states:
    • Brentuximab vedotin is recommended as an option for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if:
      • they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and
      • the company provides brentuximab vedotin according to the commercial access agreement with NHS England.
    • When using ECOG performance status, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect ECOG performance status and make any adjustments they consider appropriate.
  • Takeda believes the inclusion of the ECOG restriction is highly unfortunate and not aligned with clinical experience or consistent with how other medicines for lymphoma have been appraised. There was no discussion on this topic at either of the two appraisal committee meetings and this proposed restriction was not included in the previous ACD for consultation.  Previous access to brentuximab vedotin via the Cancer Drugs Fund (CDF) had no ECOG status restriction and Takeda is not aware on any data that would support this restriction. A very small group of patients could be significantly impacted by this decision and may face a bleak outlook.
  • Brentuximab vedotin is licensed for the treatment of R/R sALCL, a very rare and aggressive T-cell lymphoma that affects less than a 100 patients per year in the UK.  It has been available on the NHS, via the CDF since April 2013 and will now transition to baseline commissioning in the next three months for patients with R/R sALCL and a performance status of 0 or 1.
  • Patient care in R/R sALCL has been transformed following brentuximab vedotin’s introduction.  A 5-year follow up of the phase 2 trial of 58 patients showed an estimated 5-year overall survival rate of 60% (95% CI: 47%, 73%; median OS not yet reached) 2 in comparison to historical data before the availability of brentuximab vedotin that reported a median overall survival of just 3.0 months after relapse in R/R sALCL patients3
  • Professor Tim Illidge of The Christie NHS Foundation Trust, said: “I am delighted that patients can maintain long term access to brentuximab vedotin through this NICE decision.  R/R sALCL  is an aggressive lymphoma that in the past has carried an extremely  poor prognosis when initial therapy has failed and patients would succumb to their disease in a short period.  Brentuximab vedotin has transformed the outlook for such patients since it was made available on the CDF and provides hope of long term survival and improved quality of life”.
  • Jonathan Pearce, chief executive of the Lymphoma Association, said: “We are delighted to learn that NICE has reversed its previous negative draft guidance and recommended brentuximab vedotin for routine use within the NHS in England, Wales and Northern Ireland for patients with R/R sALCL. 

The decision will bring relief to sALCL patients and their families who without brentuximab vedotin would have limited treatment options. It is vital that innovative treatments are being developed and made available to lymphoma patients. We want everyone affected by lymphoma to receive the best possible treatment and care, and the more options there are to improve outcomes and quality of life for patients, the better”.

  • Adam Zaeske, Takeda UK General Manager, said: “At Takeda we are committed to ensuring all eligible patients have access to our medicines and have worked extremely hard to ensure R/R sALCL patients maintain access to brentuximab vedotin.  Overall, we are pleased with the positive NICE decision, however it is disappointing that NICE has added a last minute ECOG restriction that could result in a small number of patients no longer having access to the medicine and being left with limited options. We thank the clinical and patient community for their unwavering support during this complex review process”.

 

Further information on brentuximab vedotin can be found in the Summary of Product Characteristics (SmPC) 4 and Patient Information Leaflet (PIL) which can be obtained at www.medicines.org.uk

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 25/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.